New $120M federal center would target U.S. biopharmaceutical manufacturing gaps
In committeeH.R. 6089Latest action
Sponsor: Chrissy Houlahan · Representative · PA
AIDecoded by AI · checked against the recordRead the official text
Official title: Biomanufacturing Excellence Act of 2025
119th Congress
Topics: AI & technology
Introduced:
Read the official bill on Congress.govIn plain words
The plain-language version comes first. The official text is always the reference.
HR 6089 would award up to $120M to build a NIST-run center improving U.S. biopharmaceutical manufacturing speed, cost, and supply independence.
60-second read · 5 questions answered below
What does this do?
HR 6089 would establish a National Biopharmaceutical Manufacturing Center of Excellence administered through the National Institute of Standards and Technology (NIST). The center would focus on improving how the United States manufactures biopharmaceuticals, including vaccines, insulin, and cancer treatments made from living cells or biological organisms. It would also help move new manufacturing methods from laboratory research to large-scale commercial production and share findings with federal agencies and the public.
Who does it affect?
Workers in biotechnology and pharmaceutical industries would be directly affected, as the bill includes funding for job training programs in those fields. American drug and biotech companies, particularly smaller ones working to scale up products, would have access to the center's shared research and facilities.
Why does it matter?
The bill is aimed at making the United States more self-sufficient in producing medicines and reducing reliance on foreign manufacturing for supplies and equipment. Bridging the gap between laboratory-stage innovation and large-scale commercial production is identified as one of the biggest current challenges for American biotech companies.
What does it cost, and who pays?
The federal government would award up to $120 million to a single qualifying organization, which could be a university, a public-private partnership, or a group of such entities working together.
AI-drafted summary. Check it against the official text before you act on it.
Read the official bill on Congress.govMake the call
Where does it stand?
- IntroducedNov 18, 2025
- House committeeYou are here · Nov 18, 2025
- House vote
- Senate
- The president's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the president.
Latest action: — Referred to the House Committee on Science, Space, and Technology.